Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group
| Autor: | A Soler, Ana Carolina Caballero, Olga García, Ana Muntañola, Lourdes Escoda, Armando López-Guillermo, M Canet, Juan-Manuel Sancho, L Iserte, Blanca Sanchez-Gonzalez, Laura Magnano, M T Villalobos, Santiago Mercadal, Marc Sorigue, Tycho Baumann, Antonio Salar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Follicular lymphoma Salvage therapy Immunochemotherapy Gastroenterology 0302 clinical medicine Recurrence Antineoplastic Combined Chemotherapy Protocols Treatment Failure Lymphoma Follicular Etoposide Standard treatment Cytarabine Hematology General Medicine Middle Aged R-ESHAP Treatment Outcome 030220 oncology & carcinogenesis Disease Progression Female Rituximab medicine.drug Adult medicine.medical_specialty Methylprednisolone Relapsed Young Adult 03 medical and health sciences Internal medicine medicine Humans Aged Retrospective Studies Salvage Therapy business.industry medicine.disease Survival Analysis Transplantation refractory Drug Resistance Neoplasm Spain Cisplatin Neoplasm Grading ESHAP business 030215 immunology |
| Zdroj: | ANNALS OF HEMATOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Annals of Hematology r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol r-FISABIO. Repositorio Institucional de Producción Científica |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-020-04101-7 |
| Popis: | There is no standard treatment for relapsed follicular lymphoma (FL). Although platinum-based combinations are one of the most used treatments, few data have been reported in this setting. Our aim was to analyse R-ESHAP efficacy in relapsed FL patients. We retrospectively analysed 80 FL patients treated with R-ESHAP in the first or successive relapses. Responding patients received a stem cell transplantation following R-ESHAP. Seventeen histologically transformed patients were included. Median age was 50 years. At R-ESHAP initiation, 85% of the patients were in an advanced stage, 28% had a bulky disease and 40% had increased LDH. There were no statistically significant differences between POD24 and non-POD24 patients in terms of response to R-ESHAP (ORR 72% vs. 93%, p = 0.109). When analyzing R-ESHAP efficacy according to the response to the immediately previous line, patients achieving CR or PR had better CR rates to R-ESHAP than those who did not respond (CR of 57% vs. 15%, respectively, p = 0.009), as well as differences in OS (7.2 vs. 1.4 years, p < 0.0001) and in PFS (2.1 vs. 0.3 years, p < 0.0001). R-ESHAP is an effective treatment in relapsed FL patients who respond to the previous line and has to be considered as an adequate alternative for some patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink